



Response document for MHRA public consultation on the  
proposal to make Arthriex 750mg and 1500mg Film-coated Tablets available in Pharmacies  
Ref: ARM96

ANNEX 1

**Your details**

Name: [REDACTED]

Position (if applicable): Policy Manager

Organisation (if applicable): National Pharmacy Association

Email: [REDACTED]

**a. Do you consider that Arthriex 750mg and 1500mg Film-coated Tablets should be available as a Pharmacy medicine?**

Yes  No  Not sure

Please provide any comments or evidence to support your response:

Community Pharmacists are accessible clinicians on the high street, available over extended opening hours to provide advice on medications as well as the prevention of ill-health, without the need for an appointment.

Community pharmacists are well positioned to provide advice and support to the customer, including side-effects, potential interactions, as well as lifestyle and usage advice.

**b. Do you have any specific comments on the leaflet or the label provided in the public reclassification report? In particular:**

- **If you are a potential patient, do you find the patient information leaflet (Annex 2) and the label (Annex 3) understandable?**

Patient information leaflet (Annex 2)

The Patient information leaflets for Arthriex ( 750mg & 1500mg) appear to be comprehensive as to the uses of Arthriex , contraindications and dosage. The leaflets also make reference to seeking advice from the pharmacist and doctor.

The NPA would like to make comment on paragraph 5 of both leaflets.

In the paragraph "Do not throw away any medicines via wasterwater or household waste. Ask your pharmacist how to throw away medicines you no longer use" suggest replacing with "Do not throw away any medicines via wastewater of household waste. Return any medicines you no longer use to the pharmacist"

Label (Annex 3)

The labels for both Arthriex 750mg and Arthriex 1500mg appear to be comprehensive.

- **If you are a pharmacist or healthcare professional would you be confident to supply this product if suitable pharmacy training was provided?**

The NPA as a national body for independent community pharmacy will support its members across the UK, with various education and training tools, should this change be approved.

**c. Do you have any other comments on the reclassification?**

**d. The MHRA may publish consultation responses. Do you want your response to remain confidential?**

Yes

Partially\*

No

\*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

As a representative body we have to consult with our members as part of the consultation process, and found the tight deadline rather a challenge, particularly over the holiday period. We would encourage MHRA to allow a longer period for these consultations.

Responses can be continued onto a separate page if required. This form should be returned by email ([reclassification@mhra.gsi.gov.uk](mailto:reclassification@mhra.gsi.gov.uk)) to arrive by xxxxxx 2017. Contributions received after that date cannot be included in the exercise.